Innovating to improve access to diagnostics

Atomo Diagnostics is committed to applying its resources, technologies and know-how to help address the fundamental issues affecting the global health community today.

The company believes that innovation in diagnostics is key to improving health outcomes in countries with high disease burdens and weak or fractured healthcare systems. Community-based and self testing programs are seen by many experts as critical to achieve global targets for halting the spread of infectious disease. This is particularly true for those most at risk in the global health community, many of whom have limited access to facility-based testing services.

Designed for ease-of-use in the field

Atomo has developed easy-to-use rapid diagnostic test (RDT) platforms ideally suited for deployment in challenging and resource-poor regions, where cost effectiveness, robustness and usability are central to the success of testing programs.

Atomo works closely with frontline healthcare workers in Africa to understand the usability challenges and in-field limitations of standard RDT kits. This insight has been key to the development of Atomo’s all-in-one RDT platform technologies, with their focus on improved safety, ease-of-use and mitigation of user errors.

Crucial support from the Global Health Investment Fund

Atomo is proud to have received ongoing support from GHIF to develop its HIV at-home and point-of-care tests. GHIF is a private investment fund structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, focussed on financing global health research and development.

Products with “dual market” potential are of great interest to GHIF; i.e., those that will have value in high-income countries but also have a clear impact on public health in developing countries. The AtomoRapid HIV device was deemed of particular interest to GHIF given the significant impact it can bring to global health by improving HIV screening.